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10, with 10 being death). For most patients, MS will progress from an episodic
disorder (relapsing-remitting MS) to a more progressive state (secondary progressive
MS). We conducted a systematic review of the literature to determine how health
related quality of life, as measured by health utilities, changes with the increasing
neurological disability associated with different stages of MS. METHODS: Employing
pre-deﬁ ned search terms and inclusion/exclusion criteria, systematic searches 
were conducted in MEDLINE, EMBASE, PsycINFO, Health Economic Evaluation 
Database (HEED), NHS Economic Evaluations Database (NHS/EED), and the UK 
National Institute for Health and Clinical Excellence (NICE) website. All databases
were searched from 1 January 1993 to 5 August 2008. Data extraction was validated 
by an independent reviewer. RESULTS: We identiﬁ ed 16 studies reporting health utili-
ties associated with health states of MS. EQ-5D was the most common preference
elicitation instrument. Health utilities ranged from 0.80 to 0.89 for patients with an
EDSS score of 1, from 0.49 to 0.71 for patients with an EDSS score of 3, from 0.39 
to 0.54 for patients with an EDSS score of 6.5, and from 0.19 to 0.08 for patients
with an EDSS score of 9 with some patients valuing their health states as worse than 
death. CONCLUSIONS: MS has a signiﬁ cant impact on quality of life. Utilities 
decrease signiﬁ cantly with increasing neurological disability. Without taking into 
consideration EDSS score, there appears to be no difference in health utilities between
RRMS and SPMS patients and the variation in health utilities appears to be mainly 
explained by the severity of the disability. Utilities also decreased signiﬁ cantly during 
relapse phases.
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OBJECTIVES: Central Nervous System (CNS) studies often incorporate the use of 
patient-reported outcomes (PROs) because of the nature of disorders being studied 
and their dependence on the subjective reports of study subjects1. To date, limited 
data has been published that sheds light on the types of instruments that are collected 
electronically (ePRO) in CNS trials. This research studied the breadth and depth of 
ePRO use through the analysis of a data set containing details of ePRO use in phase 
I-IV CNS drug trials. METHODS: A study of the characteristics of ePRO use in CNS
clinical drug trials was undertaken to understand the breath of CNS disorders areas
in which ePRO is being used as well as to understand how ePRO is being used within
these trials. A dataset of 91 clinical trials was analyzed by using ﬁ elds that describe
each protocol’s key elements including ePRO instrument, Phase, Assessment Fre-
quency, Disorder and Target Population. RESULTS: The analysis determined that 
Depression and sleep disorders respectively represented 33.3% and 34% of ePRO use 
for this dataset. Overall, ePRO was used in 12 different CNS disorders. ePRO was
most often used to collect primary efﬁ cacy data (24%), but other uses included second-
ary efﬁ cacy (22%) and safety (4.4%) data. The most common reporting frequency 
was for screening or study eligibility assessment (24%); this was followed closely by 
daily (19.8%) assessment. Of interest was that 79% of the time, a named instrument 
is used as opposed to a diary or symptom questionnaire (21%). CONCLUSIONS:
This research shows that PROs are not only being collected electronically, but that
ePRO use within CNS clinical trials is both broad and deep. Limitations of this study 
include the clinical trials of this dataset which can not be necessarily generalized as 
representative of all CNS ePRO use.
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OBJECTIVES: To assess and describe the diagnostic and treatment pathways of move-
ment disorders responsive to BoNTA, Allergan Units and assess the types and number 
of health care professionals seen by patients before their movement disorder diagnosis 
was made and the length of time from onset of symptoms to diagnosis. METHODS:
Patients with movement disorders completed a 19-question survey developed by the
Canadian Movement Disorders Survey Group. Questions included patient demo-
graphics, length of time from onset of symptoms, number and types of physicians 
seen, other diagnoses made, number of patients treated with BoNTA and distance 
traveled. RESULTS: In this ﬁ nal analysis, 879 patients with movement disorders 
responsive to BoNTA were surveyed. Majority of the patients were female (72%), 
traveling an average of 69 km one-way. Most common movement disorder diagnoses 
were cervical dystonia (42%), hemifacial spasm (20%), and blepharospasm (9%).
Common diagnoses made prior to the movement disorder diagnoses were nerve/muscle 
problem (33%), stress/psychological problem (39%), tremor (16%), ﬁ bromyalgia 
(14%), TMJ (10%), joint/tendon problem (15%) and spine (10%). The average 
number of physicians seen before the movement disorder diagnosis was 3.1. Amongst
these were family physicians (78%), neurologists (71%), movement disorder special-
ists (32%), chiropractors (17%), eye care doctors (17%), physiotherapists (17%), and
neurosurgeons (10%). Most physicians who made the current movement disorder
diagnoses were neurologists (63%) and movement disorder specialists (33%). The
average time in years from onset of symptoms to movement disorder diagnosis were:
cervical dystonia 6.6, blepharospasm 4.7, hemifacial spasm 3.8, spasmodic dysphonia 
2.5, limb dystonia 8.2, Meige syndrome 2.8, generalized dystonia 1.6, oromandibular 
dystonia 2.1. 95% of patients were treated with BoNTA following their movement
disorder diagnosis. CONCLUSIONS: The number of physicians seen and length of 
time from onset to movement disorder diagnoses are considerable. Increased aware-
ness of movement disorders at the primary care level may improve these rates.
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OBJECTIVES: Brain abscess is a somewhat rare condition found more commonly in 
pediatric patients than young adults. While fatalities as a result of brain abscesses have 
decreased signiﬁ cantly in recent years, the possibility of the condition being fatal is 
very real. Early diagnosis and treatment are the keys to effectively resolving the issue. 
The purpose of this paper is to examine patient outcomes for those diagnosed with
brain abscess. METHODS: Data were taken from the National Inpatient Sample
(NIS). The data consist of pediatric patients diagnosed with brain abscesses (N  252) 
and a randomly selected control group (N  260). SAS Enterprise Guide, a statistical
software program, was used to analyze the data set and provide an overview of the
results. Methods used included one-way frequencies, statistical summaries, kernel
density estimations, and linear and logistic regression models. RESULTS: Contrary to 
other sources, the age of pediatric patients in the sample seems to play a role in the
likelihood of developing brain abscesses. Factors such as age, gender, and race were 
shown by several different methods to be not signiﬁ cant in the diagnosis. The mortality 
rate was found to be ﬁ ve times higher in the treatment group than the control sug-
gesting that while this condition may be declining with respect to deaths, the rate is 
still signiﬁ cantly higher than a random control group from the NIS database. CON-
CLUSIONS: While the mortality rate for brain abscesses is low, current procedures 
can still be improved to lower the rate further. New techniques of diagnosing brain
abscesses can also be developed with the research found in the NIS. Further studies 
should be performed in order to ﬁ nd more relationships. Finding the connection 
between these connections may lead to better preventive measures and improved
treatments for brain abscesses.
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OBJECTIVES: To assess factors associated with health-related quality of life (HRQoL) 
in MS patients after three natalizumab infusions. METHODS: MS patients, newly 
enrolled in the manufacturer’s restricted drug distribution program and participating
in a longitudinal study of their experiences with natalizumab, complete assessments
prior to treatment initiation and after the 3rd, 6th and 12th infusion. HRQoL was 
assessed with the SF-12v2 where higher physical and mental component summary 
(PCS and MCS) scores indicated improvement in HRQoL. Univariate, followed by 
multivariate, linear regression was used to identify factors associated with HRQoL
after three natalizumab infusions. The factors used in this analysis include age, clinical 
characteristics (disease duration, number of prior MS treatments) and baseline (BL) 
disease severity measures (disease step (DS), functional status, fatigue score, cognitive 
functioning (CF) score). RESULTS: At the time of this analysis 504 patients had 
completed BL and 3rd assessments. Mean age was 46.08 o 10.93, 78% of patients 
were female, and mean disease duration was 9.64 o 8.33 years. PCS and MCS scores
improved signiﬁ cantly from baseline (PCS: 34.03 versus 36.02; p  0.001) and MCS:
43.17 versus 47.22; p  0.001). Multivariate analysis indicated that higher BL PCS
scores (p  0.001), lower BL DS scores (p  0.001) and younger age (p  0.002) were 
associated with improvement in PCS scores after three natalizumab infusions. Simi-
larly, higher BL MCS (p  0.001) and BL CF scores (p  0.001) were associated with 
improvement in MCS scores after the 3rd infusion. CONCLUSIONS: Factors associ-
ated with improvement in PCS scores after the 3rd infusion were younger age, higher 
BL PCS scores, and lower BL DS scores (better ambulation) while those associated
with improvements in MCS scores were higher BL MCS scores and higher BL CF 
scores. These results suggest that initiating natalizumab in younger patients having 
lower disability and better baseline HRQoL results in greater improvements in 
HRQoL after three natalizumab infusions.
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OBJECTIVES: Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
that affects 1 million people in the United States. Several available treatments are 
effective in controlling its symptoms; however, relatively little research has examined
patient- and physician-reported PD treatment satisfaction/ease-of-use (SEU) ratings.
These post-hoc analyses examined whether improvement in PD symptoms and dis-
abilities predicted subsequent ratings of SEU with rasagiline, a selective irreversible 
monoamine oxidase type-B inhibitor. METHODS: The LEGATO trial was an open-
label study of 0.5 mg and 1.0 mg once daily rasagiline in PD patients at 38 commu-
nity-based centers in the United States. Baseline treatment determined patients’
